ABEONA THERAPEUTICS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.26 USD | +2.19% |
|
-56.94% | -34.93% |
| Apr. 23 | Sector Update: Health Care Stocks Rise Late Afternoon | MT |
| Apr. 23 | Top Midday Decliners | MT |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 273.2 | 154.7 | 49.41 | 52.9 | 124.1 | 89.18 | - | - |
| Enterprise Value (EV) 1 | 273.2 | 154.7 | 49.41 | 52.9 | 124.1 | 89.18 | 89.18 | 89.18 |
| P/E ratio | -2.17 x | -1.73 x | -0.39 x | -0.56 x | -1.98 x | -1.53 x | -1.72 x | -5.62 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | - | 15.5 x | 16.5 x | 37.4 x | 35.5 x | 89.2 x | 2.85 x | 0.84 x |
| EV / Revenue | - | 15.5 x | 16.5 x | 37.4 x | 35.5 x | 89.2 x | 2.85 x | 0.84 x |
| EV / EBITDA | - | - | - | - | - | - | - | - |
| EV / FCF | -3,951,554 x | -4,254,944 x | - | - | - | - | -1,938,640 x | 6,859,802 x |
| FCF Yield | -0% | -0% | - | - | - | - | -0% | 0% |
| Price to Book | - | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 3,341 | 3,941 | 5,865 | 17,176 | 24,773 | 27,355 | - | - |
| Reference price 2 | 81.75 | 39.25 | 8.425 | 3.080 | 5.010 | 3.260 | 3.260 | 3.260 |
| Announcement Date | 3/16/20 | 3/24/21 | 3/31/22 | 3/29/23 | 3/18/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | 10 | 3 | 1.414 | 3.5 | 1 | 31.33 | 105.8 |
| EBITDA | - | - | - | - | - | - | - | - |
| EBIT 1 | -77.09 | -81.42 | -89.84 | -50.92 | -47.14 | -56.31 | -40.87 | -12.85 |
| Operating Margin | - | -814.2% | -2,994.53% | -3,600.78% | -1,346.71% | -5,630.83% | -130.47% | -12.14% |
| Earnings before Tax (EBT) 1 | -76.28 | -84.23 | -84.94 | -39.7 | -54.19 | -60.27 | -63.67 | -26.8 |
| Net income 1 | -76.28 | -84.23 | -84.94 | -43.48 | -54.19 | -61.9 | -53.07 | -23.15 |
| Net margin | - | -842.34% | -2,831.2% | -3,074.82% | -1,548.23% | -6,190% | -169.4% | -21.87% |
| EPS 2 | -37.75 | -22.75 | -21.50 | -5.530 | -2.530 | -2.137 | -1.897 | -0.5800 |
| Free Cash Flow | -69.13 | -36.36 | - | - | - | - | -46 | 13 |
| FCF margin | - | -363.55% | - | - | - | - | -146.84% | 12.28% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 3/16/20 | 3/24/21 | 3/31/22 | 3/29/23 | 3/18/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | 3 | 0.346 | 1 | - | 0.068 | - | 3.5 | - | - | 0.25 | 0.25 | 0.25 | 0.25 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -14.87 | -46.65 | -20.59 | -8.008 | -9.38 | -12.94 | -12.04 | -11.62 | -11.33 | -13.21 | -14.2 | -14.65 | -15.05 | -15.75 |
| Operating Margin | - | -1,555.07% | -5,951.16% | -800.8% | - | -19,023.53% | - | -331.97% | - | - | -5,680% | -5,860% | -6,020% | -6,300% |
| Earnings before Tax (EBT) 1 | -7.044 | -46.68 | -20.79 | -8.295 | -9.484 | -1.126 | -9.107 | -16.65 | -11.84 | -16.59 | -14 | -14.5 | -15.43 | -16.47 |
| Net income 1 | -7.044 | -46.68 | -20.79 | -12.08 | -9.484 | -1.126 | -9.107 | -16.65 | -11.84 | -16.59 | -14.5 | -15.25 | -15.65 | -16.7 |
| Net margin | - | -1,556.1% | -6,008.96% | -1,207.7% | - | -1,655.88% | - | -475.83% | - | - | -5,800% | -6,100% | -6,260% | -6,680% |
| EPS 2 | -1.750 | -11.25 | -3.500 | -2.080 | -1.480 | - | -0.5400 | -0.9200 | -0.4800 | -0.6400 | -0.5133 | -0.5300 | -0.5567 | -0.5400 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/15/21 | 3/31/22 | 5/13/22 | 8/11/22 | 11/14/22 | 3/29/23 | 5/11/23 | 8/8/23 | 11/13/23 | 3/18/24 | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow | -69.1 | -36.4 | - | - | - | - | -46 | 13 |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex | 6.31 | 1.34 | - | - | - | - | 5 | 6 |
| Capex / Sales | - | 13.36% | - | - | - | - | 15.96% | 5.67% |
| Announcement Date | 3/16/20 | 3/24/21 | 3/31/22 | 3/29/23 | 3/18/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
3.26
USD
Average target price
20.5
USD
Spread / Average Target
+528.83%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -34.93% | 89.18M | |
| +1.51% | 42.75B | |
| +8.57% | 41.34B | |
| +49.22% | 41.61B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- ABEO Stock
- Financials Abeona Therapeutics Inc.
